The Experts below are selected from a list of 29325 Experts worldwide ranked by ideXlab platform
Nicolas Widmer - One of the best experts on this subject based on the ideXlab platform.
-
Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): An emerging role for Drug Blood Level testing?
Cancer treatment reviews, 2010Co-Authors: Margaret Von Mehren, Nicolas WidmerAbstract:Summary Imatinib is the standard of care for patients with advanced metastatic gastrointestinal stromal tumors (GIST), and is also approved for adjuvant treatment in patients at substantial risk of relapse. Studies have shown that maximizing benefit from imatinib depends on long-term administration at recommended doses. Pharmacokinetic (PK) and pharmacodynamic factors, adherence, and Drug–Drug interactions can affect exposure to imatinib and impact clinical outcomes. This article reviews the relevance of these factors to imatinib’s clinical activity and response in the context of what has been demonstrated in chronic myelogenous leukemia (CML), and in light of new data correlating imatinib exposure to response in patients with GIST. Because of the wide inter-patient variability in Drug exposure with imatinib in both CML and GIST, Blood Level testing (BLT) may play a role in investigating instances of suboptimal response, unusually severe toxicities, Drug–Drug interactions, and suspected non-adherence. Published clinical data in CML and in GIST were considered, including data from a PK substudy of the B2222 trial correlating imatinib Blood Levels with clinical responses in patients with GIST. Imatinib trough plasma Levels
Yasushi Matsuda - One of the best experts on this subject based on the ideXlab platform.
-
Development of a Liquid Chromatography-Tandem Mass Spectrometric Method for Quantification of Mycophenolic Acid and Its Glucuronides in Dried Blood Spot Samples.
Therapeutic drug monitoring, 2017Co-Authors: Hiromasa Iboshi, Hiroaki Yamaguchi, Hiroyuki Suzuki, Masafumi Kikuchi, Masaki Tanaka, Shinya Takasaki, Akiko Takahashi, Masamitsu Maekawa, Miki Shimada, Yasushi MatsudaAbstract:Background:Personalized immunosuppressive therapy, including accurate Drug dosing based on the Drug Blood Level, leads to better clinical outcomes, specifically regarding avoidance of Drug-induced adverse effects and maintenance of efficacy. Mycophenolic acid (MPA) is used as an immunosuppressant in
Margaret Von Mehren - One of the best experts on this subject based on the ideXlab platform.
-
Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): An emerging role for Drug Blood Level testing?
Cancer treatment reviews, 2010Co-Authors: Margaret Von Mehren, Nicolas WidmerAbstract:Summary Imatinib is the standard of care for patients with advanced metastatic gastrointestinal stromal tumors (GIST), and is also approved for adjuvant treatment in patients at substantial risk of relapse. Studies have shown that maximizing benefit from imatinib depends on long-term administration at recommended doses. Pharmacokinetic (PK) and pharmacodynamic factors, adherence, and Drug–Drug interactions can affect exposure to imatinib and impact clinical outcomes. This article reviews the relevance of these factors to imatinib’s clinical activity and response in the context of what has been demonstrated in chronic myelogenous leukemia (CML), and in light of new data correlating imatinib exposure to response in patients with GIST. Because of the wide inter-patient variability in Drug exposure with imatinib in both CML and GIST, Blood Level testing (BLT) may play a role in investigating instances of suboptimal response, unusually severe toxicities, Drug–Drug interactions, and suspected non-adherence. Published clinical data in CML and in GIST were considered, including data from a PK substudy of the B2222 trial correlating imatinib Blood Levels with clinical responses in patients with GIST. Imatinib trough plasma Levels
Cheng Xiao - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of Rheumatoid Arthritis Using Combination of Methotrexate and Tripterygium Glycosides Tablets-A Quantitative Plasma Pharmacochemical and Pseudotargeted Metabolomic Approach.
Frontiers in pharmacology, 2018Co-Authors: Menglei Wang, Jing Huang, Huizhen Fan, Siyu Zhao, Yisong Shu, Linlin Liu, Cheng XiaoAbstract:Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by chronic destructive synovitis and is associated with progressive disability, systemic difficulties, premature death, and socioeconomic costs. Early intervention with disease-modifying antirheumatic Drugs (DMARDs) like methotrexate (MTX) and its combination regimen would provide obvious benefits to patients, healthcare systems and society. MTX and tripterygium glycosides tablets (TGTS) are most frequently prescribed medicines for RA, and the combination of them occurs frequently in anti-RA prescriptions. While the underlying combination mechanisms and the affected variation of Drug Blood Level remain unclear. According to the American College of Rheumatology criteria for improvement, clinical evaluation following three treatment groups (i.e., MTX and TGTS mono- and combined groups) were carried out at baseline and at the end of 12 weeks in a randomized controlled clinical trial. To monitor the affected variation of Drug Blood Level and perturbation of metabolites caused by MTX plus TGTS combined to treat active RA, the collected plasma samples were analyzed using RRLC-QqQ-MS and UHPLC-QE Orbitrap HRMS instruments. As a result, thirty-nine metabolites including seven MTX-related metabolites, thirteen TGTS-related migratory ingredients and nineteen characteristic endogenous metabolites, were quantitatively determined in plasma samples of RA patients after oral administration. The potential mechanism of MTX and TGTS combination were preliminarily elucidated on the aspect of clinical biochemical test indicators integrated with quantitative plasma pharmacochemistry and the pseudotargeted metabolomics.
Lennart Gram - One of the best experts on this subject based on the ideXlab platform.
-
Antiepileptic Drug Monotherapy Designs in Clinical Trials
Epilepsia, 1997Co-Authors: Lennart GramAbstract:Evaluation of new antiepileptic Drugs (AEDs) in monotherapy used to be performed by comparative trials between new AEDs and classical AEDs. However, the majority of these studies showed no difference in outcome, which could result in conflicting interpretations. Therefore, novel designs that avoid this problem have been developed to evaluate new AEDS. Three approaches have been proposed, each with advantages and disadvantages. The attenuated active control design compares new AEDs to suboptimal doses of a control AED. However, this situation brings about ethical concerns and strict entry criteria must be applied. The presurgical design compares new AEDs to placebo treatment. Rapid dose escalation to the therapeutic Level of the new AED must he undertaken to avoid seizures resulting from extended suboptimal doses of the AED, and ethical concerns about the use of placebo also apply. The concentration controlled design is based on the assumption that a stronger correlation exists between Drug Blood Level and therapeutic response in comparison to correlation between dose and effect. In this design, patients are randomized to be treated with different Blood concentrations of a new AED, and efficacy data at these different concentrations are compared. All of these designs allow a definitive demonstration of efficacy early in the development of a new AED.
